ArticleEuropean journal of epidemiology2012
Use of glucosamine and chondroitin in relation to mortality.
Article in European journal of epidemiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 96 citations in OpenAlex.
- The Safety and Efficacy of Glucosamine and/or Chondroitin in Humans: A Systematic Review.Nutrients · 2025Pooled it
- Impact of Glucosamine Supplementation on Gut Health.Nutrients · 2021Trial
- Trial
- Supplements and Drugs Are Associated With Biological Age in a Cohort of Exceptionally Healthy Individuals.Aging cell · 2026Article
- Immunometabolic resistors of aging in long-lived golden spiny mice.Science advances · 2026Article
- Osteoarthritis as a marker and potential contributor to cardiovascular risk: a glycocalyx-cartilage axis hypothesis.Frontiers in cardiovascular medicine · 2026Article
- Glucosamine Use and Its Association with Colorectal Cancer and Mortality: A Systematic Review and Meta-Analysis.Journal of Cancer · 2026Article
- Dietary glucosamine supplement use and lower surgery risk in individuals with inflammatory bowel disease: a prospective Cohort Study.European journal of nutrition · 2025Article
- Plasma Glutaminyl-Peptide Cyclotransferase Mediates Glucosamine-Metabolism-Driven Protection Against Hypertension: A Mendelian Randomization Study.International journal of molecular sciences · 2024Article
- Association between fish oil and glucosamine use and mortality in patients diagnosed with cancer: the role of the Life Essential 8 score and cancer prognosis.Nutrition journal · 2024Article
- Endogenous chondroitin extends the lifespan and healthspan in C. elegans.Scientific reports · 2024Article
- Glucosamine and Chondroitin Use and Mortality Among Adults in the United States from 1999 to 2014.Journal of integrative and complementary medicine · 2023Article
- Association of regular glucosamine use with incident dementia: evidence from a longitudinal cohort and Mendelian randomization study.BMC medicine · 2023Article
- Nutraceutical activation of Sirt1: a review.Open heart · 2022Review
- Nutraceutical Prevention of Diabetic Complications-Focus on Dicarbonyl and Oxidative Stress.Current issues in molecular biology · 2022Review
- Neuroprotective and Proneurogenic Effects of Glucosamine in an Internal Carotid Artery Occlusion Model of Ischemia.Neuromolecular medicine · 2022Article
- Glucosamine use, smoking and risk of incident chronic obstructive pulmonary disease: a large prospective cohort study.The British journal of nutrition · 2022Article
- The Role of Glucosamine and Chondroitin Sulfate in the Prevention of Colorectal Cancer: A Systematic Review.Cureus · 2022Review
- Nutraceutical and Dietary Strategies for Up-Regulating Macroautophagy.International journal of molecular sciences · 2022Review
- Association between glucosamine use and cancer mortality: A large prospective cohort study.Frontiers in nutrition · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
Glucosamine and chondroitin are products commonly used by older adults in the US and Europe. There is limited evidence that they have anti-inflammatory properties, which could provide risk reduction of several diseases. However, data on their long-term health effects is lacking. To evaluate whether use of glucosamine and chondroitin are associated with cause-specific and total mortality. Participants (n = 77,510) were members of a cohort study of Washington State (US) residents aged 50-76 years who entered the cohort in 2000-2002 by completing a baseline questionnaire that included questions on glucosamine and chondroitin use. Participants were followed for mortality through 2008 (n = 5,362 deaths). Hazard ratios (HR) for death adjusted for multiple covariates were estimated using Cox models. Current (baseline) glucosamine and chondroitin use were associated with a decreased risk of total mortality compared to never use. The adjusted HR associated with current use of glucosamine (with or without chondroitin) was 0.82 (95 % CI 0.75-0.90) and 0.86 (95 % CI 0.78-0.96) for chondroitin (included in two-thirds of glucosamine supplements). Current use of glucosamine was associated with a significant decreased risk of death from cancer (HR 0.87 95 % CI 0.76-0.98) and with a large risk reduction for death from respiratory diseases (HR 0.59 95 % CI 0.41-0.83). Use of glucosamine with or without chondroitin was associated with reduced total mortality and with reductions of several broad causes of death. Although bias cannot be ruled out, these results suggest that glucosamine may provide some mortality benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.